Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03462719
Title A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Janssen Research & Development, LLC

chronic lymphocytic leukemia



Chlorambucil + Obinutuzumab

Ibrutinib + Venetoclax

Age Groups: senior | adult
Covered Countries USA | CAN

Additional content available in CKB BOOST